证券代码：301382 证券简称：蜂助手 公告编号：2025-054 蜂助手股份有限公司 2025年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示: 1、本次股东大会无否决或变更议案的情况。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、召开时间： （1）现场会议日期和时间：2025年6月30日（星期一）下午14:30 （2）网络投票日期和时间：2025 年 6 月 30 日 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025年6月30 日9:15-9:25、9:30-11:30、13:00-15:00；通过深圳证券交易所互联网投票系统 投票的具体时间为：2025年6月30日9:15至15:00期间的任意时间。 2、召开地点：广东省广州市天河区黄埔大道660号汇金国际金融中心10楼6 号会议室。 3、召开方式：本次股东大会采用现场表决与网络投票相结合的方式召开。 4、召集人：公司第四届董事会。 5、主持人：董事长罗洪鹏先生。 6、本次会议的召集、召开符合《中 ...

证券代码：301382 证券简称：蜂助手 公告编号：2025-055 蜂助手股份有限公司 关于减少注册资本暨通知债权人公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 蜂助手股份有限公司（以下简称"公司"）于2025年6月11日召开了第四届董 事会第六次会议，审议通过了《关于2024年限制性股票激励计划首次授予部分第一 个解除限售期解除限售条件未成就、第一个归属期归属条件未成就、回购注销及作 废部分限制性股票相关事项的议案》，2025年6月30日，公司召开了2025年第一次 临时股东大会，审议通过了上述议案。详细内容详见公司于2025年6月12日在巨潮 资讯网（www.cninfo.com.cn）披露的《第四届董事会第六次会议决议公告》（公 告编号：2025-049）、《关于2024年限制性股票激励计划首次授予部分第一个解除 限售期解除限售条件未成就、第一个归属期归属条件未成就、回购注销及作废部分 限制性股票相关事项的公告》（公告编号：2025-047）。 鉴于公司第一类限制性股票第一个解除限售期因2024年度业绩考核目标未达成 不能解除限售，公司股东大会 ...

证券代码：301382 证券简称：蜂助手 公告编号：2025- 053 蜂助手股份有限公司 关于持股 5%以上股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 （二）股东股份累计质押情况 截至公告披露日，公司股东海峡创新所持股份累计质押情况如下： | | | | | | | 已质押股份 | | 未质押股份 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 情况 | | 情况 | | | | 持股数 | 持 | 累计质 | 占其 | 占公 | | | | | | 股东 | 量 | 股 | 押股份 | 所持 | 司总 | 已质押股 | | 未质押 | | | 名称 | （股） | 比 | 数量 | 股份 | 股本 | 份限售和 | 占已质 | 股份限 | 占未质 | | | | 例 | （股） | 比例 | 比例 | 冻结、标 | 押股份 | 售和冻 | 押股份 | | | | | | | | 记数量 | 比例 | 结数量 | 比 ...

Investment Rating - Industry rating: Recommended [5] Core Insights - The beauty sector experienced a stable conclusion during the 618 shopping festival, with significant changes in platform and brand dynamics driven by reduced commission policies and interest-based content ecosystems [1][2] - The total GMV for beauty products across four major e-commerce platforms (Taobao, JD, Douyin, Kuaishou) during the 618 period was between 600-700 billion yuan, reflecting a year-on-year growth of over 10% [1] - Taobao maintained the largest market share at 41.3%, followed by Douyin at 35.7%, JD at 14.8%, and Kuaishou at 8.2% [1][13] Summary by Sections E-commerce Platform Dynamics - Douyin's beauty segment is rapidly growing, supported by merchant subsidies and interest-driven consumer engagement, achieving double-digit growth [2] - Douyin's promotional strategies included a 1.4 billion yuan subsidy for merchants in May, with individual merchant reductions reaching up to 2.99 million yuan [2] Skincare and Makeup Categories - In the skincare category, domestic brands like Proya and Han Shu led the market, maintaining their top positions on Taobao and Douyin [3] - The top five brands in the skincare category on Taobao remained stable, with Proya and Han Shu continuing to dominate [3] - In the makeup and fragrance category, new domestic brands are emerging, with Ti Luo Wei achieving rapid growth by focusing on base makeup products [4] International and Domestic Brand Strategies - International brands are performing well due to localized marketing strategies and a willingness to engage with local consumers [8] - Domestic brands are expected to break out of the competitive cycle focused on ingredients and efficacy, emphasizing brand influence and comprehensive user experience [8] Investment Recommendations - Focus on domestic companies with strong brand equity and comprehensive channel strategies, particularly Proya and Han Shu [9] - Highlight technology-driven skincare brands like Betaini and Juzi Biology that target specific consumer needs [9] - Consider daily chemical brands with strong cost-performance ratios and excellent management of emerging channels, such as Runben and Dengkang [9]

Core Insights - The Ministry of Industry and Information Technology and the National Development and Reform Commission have initiated a program to cultivate over 20 pilot platforms for biomanufacturing by 2027, aiming to facilitate industrial scale-up [1] - Significant technological breakthroughs and industrial layouts are emerging in the biomanufacturing sector, with advancements in areas such as polysulfone plastic recycling and wool sterol synthesis [1] - The synergy between policy support and industrial development is accelerating the transition of biomanufacturing from laboratory research to large-scale industrialization, showcasing a vibrant development chain of "technological breakthroughs - policy support - capital influx" [1] Industry Developments - Synthetic biology is reshaping production models in biomanufacturing, enabling tasks that traditional biotechnologies cannot achieve, while also providing more efficient and environmentally friendly biosynthesis solutions [1] - Companies like Huaxi Biological and Yikole are extending their capabilities in synthetic biology, with Huaxi focusing on the supply chain of hyaluronic acid and Yikole leveraging CRISPR-Cas9 technology for precise gene editing [2][3] - The integration of synthetic biology with traditional industries is seen as a means to enhance productivity and create new growth opportunities, rather than a conflict [4] Technological Innovations - Companies are developing comprehensive systems in synthetic biology, focusing on tool, platform, and product integration, with significant advancements in production efficiency [3] - AI is playing a crucial role in enhancing research efficiency in synthetic biology, with companies establishing AI teams to optimize data collection and algorithm development [7] - The use of AI in the design and testing phases of synthetic biology is expected to significantly reduce research timelines and costs, improving overall productivity [7] Market Trends - The biomanufacturing industry is experiencing a wave of policy support, with various local governments implementing initiatives to promote the industrialization of synthetic biology [8] - The market for biomanufacturing in China is projected to approach 1.8 trillion yuan by 2030, indicating substantial growth potential [8] - Recent financing trends show an acceleration in investments in domestic synthetic biology companies, with nearly a hundred firms securing new funding at the beginning of 2025 [8] Future Outlook - The synthetic biology sector is anticipated to undergo rapid technological iterations and deeper application expansions in the next 3-5 years, driven by AI advancements [9] - Companies are encouraged to focus on quality improvement and original design rather than mere scale expansion, to avoid resource wastage and industry chaos [9] - The industry is expected to face dual challenges in technology transfer and industrialization, particularly in constructing microbial cell factories and overcoming engineering challenges in fermentation and purification [10]

Core Viewpoint - JINBO Biotech is the only company in China with three Class III certifications for injectable recombinant humanized collagen, leading the development of innovative medical materials and aiming to become a global leader in life materials [1][2]. Group 1: Product Development and Innovation - The company has successfully developed a full range of recombinant type III humanized collagen products, including freeze-dried fibers, solutions, and gels, establishing a comprehensive product system [2][3]. - JINBO Biotech's research has led to the first large-scale production of recombinant type III humanized collagen with a 164.88° triple helix structure, marking a significant breakthrough in the field [2][3]. - The company emphasizes the importance of eliminating immunogenicity and achieving large-scale production of collagen materials to meet safety and efficacy demands in medical applications [2][3]. Group 2: Research and Development Investment - In 2024, JINBO Biotech plans to invest 123 million yuan in R&D, an increase of 18.71% year-on-year, representing 8.52% of its revenue [4]. - The company is focusing on various types of humanized collagen projects, with some products already entering clinical trials [4][5]. Group 3: International Collaboration and Standards - JINBO Biotech collaborates with leading companies like L'Oréal to enhance global recognition of its technologies and promote international market penetration [5]. - The company has taken a leading role in establishing international standards for medical devices made from bioengineered materials, enhancing China's technological influence in this field [5]. Group 4: Technological Advancements and AI Integration - The company has established a FAST database for humanized collagen, significantly improving R&D efficiency through AI technology, reducing the time for data screening from one month to one day [6]. - JINBO Biotech integrates advanced technologies such as AlphaFold for protein structure prediction and has established a smart laboratory to ensure data reliability and enhance R&D capabilities [6].

Core Viewpoint - The company, Fengzhushou, announced the acquisition of a 30% stake in Guangdong Fengdang Technology Co., Ltd. from Guangzhou Xiaodang Intelligent Technology Co., Ltd. for a total of RMB 205.95 million, increasing its ownership from 70% to 100% [1] Group 1: Transaction Details - The acquisition involves purchasing 20.77 million shares of Fengdang Technology, representing 30% of its total equity [1] - The transaction is not classified as a related party transaction or a major asset restructuring under relevant regulations, thus does not require shareholder approval [1] - The valuation of Fengdang Technology's total equity was assessed at RMB 686.52 million as of May 31, 2025 [2] Group 2: Financial Performance - Fengdang Technology reported total assets of RMB 716.68 million and RMB 714.07 million as of December 31, 2024, and March 31, 2025, respectively, with total liabilities of RMB 323.22 million and RMB 323.08 million [2] - The company did not generate any revenue in 2024 and the first quarter of 2025, with operating losses of RMB 4.54 million and RMB 2.47 million, respectively [2] Group 3: Strategic Objectives - The acquisition aims to enhance the company's long-term development by leveraging local government policies for "headquarters building" and integrating the supply chain for efficient resource allocation [3] - The company plans to utilize the headquarters building to optimize office, research, and operational spaces, thereby accelerating project implementation and driving innovation [3] - The transaction is based on a fair valuation and is expected to have no significant adverse impact on the company's financial condition or operating results [3] Group 4: Historical Financial Data - From 2021 to 2024, the company reported revenues of RMB 715 million, RMB 879 million, RMB 1.179 billion, and RMB 1.539 billion, with net profits of RMB 105 million, RMB 126 million, RMB 142 million, and RMB 134 million, respectively [4] - The company went public on May 17, 2023, raising a net amount of RMB 895.99 million, exceeding its initial fundraising target by RMB 442.18 million [4][5]

证券代码：301382 证券简称：蜂助手 公告编号：2025-047 蜂助手股份有限公司 关于 2024 年限制性股票激励计划首次授予部分第一个解除限售期解 除限售条件未成就、第一个归属期归属条件未成就、回购注销及作废 部分限制性股票相关事项的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示： 蜂助手股份有限公司（以下简称"公司"）2025 年 6 月 11 日召开了第四届 董事会第六次会议和第四届监事会第五次会议，审议通过《关于 2024 年限制性 股票激励计划首次授予部分第一个解除限售期解除限售条件未成就、第一个归属 期归属条件未成就、回购注销及作废部分限制性股票相关事项的议案》，该议案 尚需提交公司股东大会审议。现将相关事项公告如下： 一、 本激励计划已履行的相关审批程序 三届监事会第十五次会议，审议并通过《关于公司<2024 年限制性股票激励计划 （草案）>及摘要的议案》、《关于公司<2024 年限制性股票激励计划实施考核 管理办法>的议案》、《关于提请股东大会授权董事会办理 2024 年限制性股票激 励计划有关事项的议案》。 期为自 ...

（以下简称《公司法》）等相关法律法规和《蜂助手股份有限公司章 程》（以下简称《公司章程》）的规定。 二、监事会会议审议情况 证券代码：301382 证券简称：蜂助手 公告编号：2025-050 蜂助手股份有限公司 第四届监事会第五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 会第五次会议（以下简称"本次会议"）在公司 9 楼会议室以现场结合通讯方式 召开。本次会议经全体监事同意豁免会议通知期限，现场发出会议通知。本次会 议应出席监事 3 名，实际出席监事 3 名，董事会秘书列席。会议由公司监事会主 席姚超创先生召集和主持。本次会议的召集、召开和表决程序符合《中华人民共 和国公司法》 （二）审议通过《关于调整 2024 年限制性股票激励计划公司层面业绩考核 目标的议案》 经审核，监事会认为：此次调整符合《上市公司股权激励管理办法》和公司 《2024 年限制性股票激励计划（草案）》等相关规定，调整程序合法合规，不 存在损害公司及股东特别是中小股东利益的情形。监事会同意公司对 2024 年限 制性股票激励计划中 2025 年 ...

蜂助手（301382）公告，公司于2025年6月11日召开董事会，审议通过购买广州小当持有的丰当科技 2.07亿股股权，占丰当科技总股本的30%，交易金额为2.06亿元。本次交易完成后，蜂助手持有丰当科 技的股权将由4.83亿股上升至6.9亿股，占总股本的比例由70%上升至100%。蜂助手将以自筹资金支付 交易金额。本次交易不涉及关联交易，不构成重大资产重组。 ...